University of Miami - Desai Sethi Urology Institute, Coral Gables, Florida, United States.
Departamento de Urologia - Beneficência Portuguesa de São Paulo, São Paulo, SP, Brasil.
Int Braz J Urol. 2024 Jul-Aug;50(4):504-506. doi: 10.1590/S1677-5538.IBJU.2024.0222.
INTRODUCTION: Obstructive azoospermia occurs when there is a blockage in the male reproductive tract, leading to a complete absence of sperm in the ejaculate. It constitutes around 40% of all cases of azoospermia (1, 2). Blockages in the male reproductive tract can arise from either congenital or acquired factors, affecting various segments such as the epididymis, vas deferens, and ejaculatory ducts (3). Examples of congenital causes encompass conditions like congenital bilateral absence of the vas deferens and unexplained epididymal blockages (4). Acquired instances of obstructive azoospermia may result from factors like vasectomy, infections, trauma, or unintentional injuries caused by medical procedures (5). This complex condition affecting male fertility, presents two main treatment options: microsurgical reconstruction and surgical extraction of sperm followed by in vitro fertilization (IVF). Microsurgical reconstruction proves to be the most cost-effective option for treating obstructive azoospermia when compared with assisted reproductive techniques (6, 7). However, success rates of reconstruction defined by patency are as high as 99% for vasovasostomy (VV) but decline to around 65% if vasoepididymostomy (VE) is required (8, 9). Thus, continued refinement in technique is necessary in order to attempt to improve patency for patients undergoing VE. In this video, we show a comprehensive demonstration of microsurgical VE, highlighting the innovative epididymal occlusion stitch. The goal of this innovative surgical technique is to improve outcomes for VE. MATERIALS AND METHODS: The patient is a 39-year-old male diagnosed with obstructive azoospermia who presents for surgical reconstruction via VE. His partner is a 37-years-old female with regular menstrual cycles. The comprehensive clinical data encompasses a range of factors, including FSH levels, results from semen analysis, and outcomes from testicular sperm aspiration. This thorough exploration aims to provide a thorough understanding of our innovative surgical technique and its application in addressing complex cases of obstructive azoospermia. RESULTS: The procedure was started on the right, the vas deferens was identified and transected. The abdominal side of the vas was intubated and a vasogram performed, there was no obstruction. There was no fluid visible from the testicular side of the vas for analysis, thus we proceeded with VE. Upon inspection of the epididymis dilated tubules were identified. After selecting a tubule for VE, two 10-0 nylon sutures were placed, and it was incised. Upon inspection of the fluid motile sperm was identified. After VE, we performed a novel epididymal occlusion stitch technique. This was completed distal to the anastomosis by placing a 7-0 prolene through the tunica of the epididymis from the medial to lateral side. This stitch was then tightened down with the goal to largely occlude the epididymis so that sperm will preferentially travel through the anastomosis. The steps were then repeated on the left. At 3-month follow up, the patient had no change in testicular size as compared with preoperative size (18cc), he had no testicular or incisional discomfort, and on semen analysis he had presence of motile sperm. After 3 months post-surgery, the patient had motile sperm seen on semen analysis. DISCUSSION: The introduction of a novel epididymal occlusion stitch demonstrates a targeted strategy to enhance the success of microscopic VE. Encouragingly, a 3-month post-surgery follow-up reveals the presence of motile sperm, reinforcing the potential efficacy of our approach. This is promising given the historical lower patency, delayed time to patency, and higher delayed failure rates that patients who require VE experience (10). In total, 40% of all azoospermia cases can be attributed to obstruction. The conventional treatments for obstructive azoospermia involve microsurgical reconstruction and surgical sperm retrieval followed by IVF. While microsurgical reconstruction has proven to be economically viable, the quest for enhanced success rates has led to the exploration of innovative techniques. Historically, the evolution of VV and VE procedures, initially performed in the early 20th century, laid the foundation for contemporary microsurgical approaches (11). Notably, the microscopic VV demonstrated significant improvements in patency rates and natural pregnancy likelihood, as evidenced by the seminal Vasovastomy Study Group study in 1991 (8). In contemporary literature, success rates particularly for VE remain unchanged for the past three decades since the original published success rates by the Vasectomy Reversal Study Group (12). VE is associated with a longer time to patency as well with patients taking 2.8 to 6.6 months to have sperm return to ejaculate as compared to 1.7 to 4.3 months for those undergoing VV. Additionally, of those patients who successfully have sperm return to the ejaculate after VE up to 50% will have delayed failure compared to 12% for those undergoing VV who are patent. Finally, of those who experience delayed failure after undergoing VE it usually occurs earlier with studies reporting as early as 6 months post-operatively (10). Given the lack of improvement and significantly worsened outcomes with VE further surgical refinement is a constant goal for surgeons performing this procedure. CONCLUSION: In conclusion, this video is both a demonstration and a call to action for commitment to surgical innovation. We aim to raise the bar in VE success rates, ultimately bringing tangible benefits to patients and contributing to the ongoing evolution of reproductive medicine. The novel epididymal occlusion stitch emerges as a beacon of progress, promising not only enhanced safety but also potential reductions in patency time. Surgical excellence and methodological refinement, as exemplified in this video, lay the foundation for a future where male reproductive surgery continues to break new ground.
介绍:当男性生殖管道出现阻塞时,会导致精液中完全没有精子,从而发生梗阻性无精子症。这种情况约占无精子症病例的 40%(1,2)。男性生殖管道的阻塞可以由先天性或后天性因素引起,影响到附睾、输精管和射精管等不同部位(3)。先天性原因包括先天性双侧输精管缺如和不明原因的附睾阻塞等(4)。后天性梗阻性无精子症可能由输精管结扎术、感染、创伤或医疗程序引起的意外损伤等因素导致(5)。这种影响男性生育能力的复杂情况有两种主要的治疗选择:显微镜下重建和手术提取精子后进行体外受精(IVF)。与辅助生殖技术相比,显微镜下重建被证明是治疗梗阻性无精子症最具成本效益的选择(6,7)。然而,根据通畅性定义,吻合术的成功率高达 99%(即输精管吻合术),但如果需要进行附睾吻合术,则成功率下降到约 65%(8,9)。因此,为了提高需要进行附睾吻合术的患者的通畅率,需要不断改进技术。在这个视频中,我们全面展示了显微镜下附睾吻合术,重点介绍了创新的附睾阻塞缝合技术。该创新手术技术的目标是改善附睾吻合术的结果。 材料和方法:患者是一名 39 岁的男性,被诊断为梗阻性无精子症,他需要通过附睾吻合术进行手术重建。他的伴侣是一名 37 岁的女性,月经周期规律。全面的临床数据包括一系列因素,包括 FSH 水平、精液分析结果和睾丸精子抽吸结果。这项全面的研究旨在深入了解我们的创新手术技术及其在治疗复杂梗阻性无精子症病例中的应用。 结果:手术首先在右侧进行,找到输精管并进行切断。将输精管的腹部侧插管,并进行输精管造影,没有发现阻塞。从睾丸侧的输精管中没有发现可见的液体进行分析,因此我们进行了附睾吻合术。检查附睾时,发现扩张的小管。选择一个小管进行附睾吻合术时,放置了两个 10-0 尼龙缝线,并进行切开。检查液体时,发现有活动精子。附睾吻合术完成后,我们采用了一种新的附睾阻塞缝合技术。在吻合术远端,通过从内侧到外侧将 7-0 prolene 通过附睾的被膜穿过,完成了这个技术。然后收紧缝线,目标是使附睾大部分阻塞,以便精子优先通过吻合术。然后在左侧重复这些步骤。在 3 个月的随访中,与术前相比,患者的睾丸大小没有变化(18cc),他没有睾丸或切口不适,精液分析显示有活动精子。手术后 3 个月,精液分析显示有活动精子。 讨论:引入新的附睾阻塞缝合技术表明了一种针对提高显微镜下附睾吻合术成功率的策略。令人鼓舞的是,术后 3 个月的随访显示有活动精子,这增强了我们方法的潜在效果。考虑到需要进行附睾吻合术的患者的通畅率较低、通畅时间延迟和较高的延迟失败率(10),这是很有希望的。总的来说,40%的无精子症病例可以归因于梗阻。梗阻性无精子症的传统治疗方法包括显微镜下重建和手术提取精子后进行 IVF。虽然显微镜下重建已经被证明具有经济可行性,但为了提高成功率,已经探索了创新技术。历史上,早期 20 世纪进行的 VV 和 VE 手术的发展为当代的显微手术方法奠定了基础(11)。特别是,1991 年 Vasovastomy Study Group 的研究表明,显微镜下 VV 显著提高了通畅率和自然妊娠的可能性(8)。在当代文献中,VE 的成功率自 Vasectomy Reversal Study Group 最初发表的成功率以来,近三十年来一直没有变化(12)。VE 与更长的通畅时间相关,与接受 VV 的患者相比,患者需要 2.8 到 6.6 个月才能使精子返回精液,而接受 VV 的患者需要 1.7 到 4.3 个月(12)。此外,在那些成功使精子返回精液的患者中,有多达 50%的患者会出现延迟失败,而接受 VV 的患者中只有 12%的患者会出现这种情况(12)。最后,在接受 VE 后出现延迟失败的患者中,通常在术后 6 个月左右就会出现(10)。由于 VE 并没有改善,而且结果明显恶化,因此对进行该手术的外科医生来说,进一步的手术改进是一个持续的目标。 结论:总之,这个视频既是展示,也是对手术创新的呼吁。我们的目标是提高 VE 成功率,最终为患者带来切实的利益,并为生殖医学的不断发展做出贡献。新的附睾阻塞缝合技术是进步的象征,不仅有望提高安全性,还可能缩短通畅时间。正如这个视频所展示的,手术卓越性和方法学的改进为男性生殖手术不断开拓新天地奠定了基础。
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2001
Cochrane Database Syst Rev. 2022-5-20
Investig Clin Urol. 2025-7
Arch Ital Urol Androl. 2025-6-30
Health Technol Assess. 2024-10
Int Braz J Urol. 2021
Basic Clin Androl. 2019-4-23
Spermatogenesis. 2014-3-31
Int Braz J Urol. 2012
Int Braz J Urol. 2011